Article Text

Download PDFPDF
Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathy
  1. Jay Ramchand1,2,
  2. Thalys Sampaio Rodrigues1,
  3. Matias B Yudi1,2,
  4. Louise M Burrell1,2
  1. 1 Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
  2. 2 Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia
  1. Correspondence to Dr Jay Ramchand, Department of Medicine, Department of Cardiology, University of Melbourne, Parkville VIC 3010, Australia; jay.ramchand{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor

We read with interest the article by Huang et al 1 entitled ‘Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy’. 

The major influence of an activated renin-angiotensin system is recognised in patients with atrial fibrillation (AF),2 but it is important to highlight that the observational nature of the present study does not allow for the causal conclusion alluded to in the title.

Several other …

View Full Text


  • Contributors JR: conceptualisation, writing. TSR: writing. MBY: writing, reviewing. LMB: writing, reviewing.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles